Literature DB >> 14685058

Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France.

Marie-Laure Chaix1, Diane Descamps, Martine Harzic, Véronique Schneider, Christiane Deveau, Catherine Tamalet, Isabelle Pellegrin, Jacques Izopet, Annick Ruffault, Bernard Masquelier, Laurence Meyer, Christine Rouzioux, Françoise Brun-Vezinet, Dominique Costagliola.   

Abstract

OBJECTIVE: To evaluate the frequency of drug-resistant HIV-1 viral strains from patients presenting with primary infection in 1999-2000 and to survey the molecular epidemiology of these viruses circulating in France.
METHODS: Resistance mutations were detected by sequencing the reverse transcriptase and the protease genes in plasma samples from 249 individuals. Phylogenetic analysis was performed on the reverse transcriptase genes.
RESULTS: Ten per cent of patients [26/249; 95% confidence interval (CI) 7-15%] presented with virus mutations associated with resistance to at least one antiretroviral drug. The distribution of the resistance mutations was as follows: to nucleoside reverse transcriptase inhibitors in 19 (8%; 95% CI 5-12%) and to non-nucleoside reverse transcriptase inhibitors in 10 (4%; 95% CI 2-7%). Primary resistance mutations to protease inhibitors were detected in 14 (6%; 95% CI 3-9%). Twelve patients (5%; 95% CI 3-8%) presented with virus harbouring mutations associated with resistance to two or three classes of antiretroviral drugs. The median HIV RNA in plasma at enrollment was lower in patients with one or more drug resistance mutations than in patients with no mutations (5.05 log versus 5.47 log, P = 0.05). Phylogenetic analysis revealed that 19% (14-24%) of patients harboured HIV-1 non-B subtype strains; this proportion remained high when Caucasian patients only were considered (14%).
CONCLUSION: This study, performed within the French network on HIV-1 primary infection survey, revealed no change in the frequency of resistant viral strains over time, but showed an increasing prevalence of non-B subtypes overall and among Caucasian individuals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14685058     DOI: 10.1097/00002030-200312050-00011

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

Review 1.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Authors:  Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

2.  Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.

Authors:  Marie-Laure Chaix; Didier Koumavi Ekouevi; Gilles Peytavin; François Rouet; Besigin Tonwe-Gold; Ida Viho; Laurence Bequet; Clarisse Amani-Bosse; Hervé Menan; Valériane Leroy; Christine Rouzioux; François Dabis
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

3.  Use of sequence data generated in the Bayer Tru Gene genotyping assay to recognize and characterize non-subtype-b human immunodeficiency virus type 1 strains.

Authors:  Diane L Hirigoyen; Charles P Cartwright
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China.

Authors:  Sihong Xu; Jingyun Li; Zuoyi Bao; Hui Xing; Ping Zhong; Hanping Li; Haiwei Zhou; Xinping Li; Sharon Wu; Aijing Song; Xiuhua Li; Jianhui Nie; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

5.  High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.

Authors:  Florence Doualla-Bell; Ava Avalos; Bluma Brenner; Tendani Gaolathe; Madisa Mine; Simani Gaseitsiwe; Maureen Oliveira; Daniella Moisi; Ndwapi Ndwapi; Howard Moffat; Max Essex; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

Review 6.  Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.

Authors:  Sonya J Snedecor; Lavanya Sudharshan; Katherine Nedrow; Abhijeet Bhanegaonkar; Kit N Simpson; Seema Haider; Richard Chambers; Charles Craig; Jennifer Stephens
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-08       Impact factor: 2.205

7.  Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection.

Authors:  J Ghosn; C Deveau; C Goujard; I Garrigue; N Saïchi; J Galimand; Z Nagy; C Rouzioux; L Meyer; M-L Chaix
Journal:  Sex Transm Infect       Date:  2006-08-21       Impact factor: 3.519

8.  Clinically relevant genotype interpretation of resistance to didanosine.

Authors:  Anne-Geneviève Marcelin; Philippe Flandre; Juliette Pavie; Nathalie Schmidely; Marc Wirden; Olivier Lada; Dan Chiche; Jean-Michel Molina; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

9.  HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America.

Authors:  Alessia Lai; Francesco R Simonetti; Gianguglielmo Zehender; Andrea De Luca; Valeria Micheli; Paola Meraviglia; Paola Corsi; Patrizia Bagnarelli; Paolo Almi; Alessia Zoncada; Stefania Paolucci; Angela Gonnelli; Grazia Colao; Danilo Tacconi; Marco Franzetti; Massimo Ciccozzi; Maurizio Zazzi; Claudia Balotta
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

10.  Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.

Authors:  Dimitrios Paraskevis; Oliver Pybus; Gkikas Magiorkinis; Angelos Hatzakis; Annemarie Mj Wensing; David A van de Vijver; Jan Albert; Guiseppe Angarano; Birgitta Asjö; Claudia Balotta; Enzo Boeri; Ricardo Camacho; Marie-Laure Chaix; Suzie Coughlan; Dominique Costagliola; Andrea De Luca; Carmen de Mendoza; Inge Derdelinckx; Zehava Grossman; Osama Hamouda; Im Hoepelman; Andrzej Horban; Klaus Korn; Claudia Kücherer; Thomas Leitner; Clive Loveday; Eilidh Macrae; I Maljkovic-Berry; Laurence Meyer; Claus Nielsen; Eline Lm Op de Coul; Vidar Ormaasen; Luc Perrin; Elisabeth Puchhammer-Stöckl; Lidia Ruiz; Mika O Salminen; Jean-Claude Schmit; Rob Schuurman; Vincent Soriano; J Stanczak; Maja Stanojevic; Daniel Struck; Kristel Van Laethem; M Violin; Sabine Yerly; Maurizio Zazzi; Charles A Boucher; Anne-Mieke Vandamme
Journal:  Retrovirology       Date:  2009-05-20       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.